Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAME
NCT05053750Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2021
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of zoledronic acid in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Percentage changes in macrophage count. Started Dec 2021; status: active, not recruiting.
02
Drugs
zoledronic acid
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05053750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05053750.